Technical Analysis for ALLR - Allarity Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | -1.43% | |
| Narrow Range Bar | Range Contraction | -1.43% | |
| Stochastic Reached Oversold | Weakness | -1.43% |
| Alert | Time |
|---|---|
| Up 2% | about 23 hours ago |
| Up 1% | about 23 hours ago |
| 60 Minute Opening Range Breakout | 1 day ago |
| Down 5% | 1 day ago |
| Down 3% | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/15/2023
Allarity Therapeutics, Inc. Description
Allarity Therapeutics A/S develops various therapeutic candidates for the treatment of cancer using drug-specific companion diagnostics (cDx) generated by its drug response predictor technology. Its lead therapeutic candidate is dovitinib, a second-generation pan-tyrosine kinase inhibitor with the ability to inhibit numerous classes of tumor-driving tyrosine kinases, including FGFR, VEGFR, PDGFR, c-Kit, Flt-3, and CSF-1. The company's therapeutic candidates also include stenoparib, selective inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase; and IXEMPRA, a selective microtubule inhibitor that interferes with cancer cell division through mitotic arrest. It also developing other therapeutic candidates comprising LiPlaCis, a targeted liposomal formulation of Cisplatin; 2X-111, a targeted liposomal formulation of Doxorubicin; and Irofulven, a DNA damaging agent. The company was founded in 2004 and is headquartered in Horsholm, Denmark.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Health Sciences Drugs Treatment Of Cancer Enzymes Protein Kinase Inhibitor Tyrosine Kinase Doxorubicin Liposome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 660.0 |
| 52 Week Low | 1.26 |
| Average Volume | 679,420 |
| 200-Day Moving Average | 72.61 |
| 50-Day Moving Average | 2.64 |
| 20-Day Moving Average | 1.54 |
| 10-Day Moving Average | 1.50 |
| Average True Range | 0.28 |
| RSI (14) | 29.58 |
| ADX | 32.87 |
| +DI | 20.40 |
| -DI | 22.76 |
| Chandelier Exit (Long, 3 ATRs) | 1.42 |
| Chandelier Exit (Short, 3 ATRs) | 2.09 |
| Upper Bollinger Bands | 1.75 |
| Lower Bollinger Band | 1.32 |
| Percent B (%b) | 0.13 |
| BandWidth | 27.63 |
| MACD Line | -0.31 |
| MACD Signal Line | -0.38 |
| MACD Histogram | 0.0726 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.56 | ||||
| Resistance 3 (R3) | 1.56 | 1.49 | 1.53 | ||
| Resistance 2 (R2) | 1.49 | 1.45 | 1.50 | 1.52 | |
| Resistance 1 (R1) | 1.44 | 1.42 | 1.44 | 1.44 | 1.51 |
| Pivot Point | 1.37 | 1.37 | 1.38 | 1.38 | 1.37 |
| Support 1 (S1) | 1.32 | 1.33 | 1.32 | 1.32 | 1.25 |
| Support 2 (S2) | 1.25 | 1.30 | 1.26 | 1.24 | |
| Support 3 (S3) | 1.20 | 1.25 | 1.23 | ||
| Support 4 (S4) | 1.20 |
